Our results indicated that SGLT2 inhibitors could significantly reduce the risk of hospitalization due to heart failure or cardiovascular death in patients with stage 3/4 CKD (HR 0.74, [95% CI 0.69–0.80]), which further confirms the cardiovascular benefit of SGLT2 inhibitors in patients with poor kidney function. This evidence concerns the gene SLC5A2 and heart failure.